Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 3, 1998, Pages 237-247

  Greenblatt, David J ^a   Wright, C Eugene ^b   Von Moltke, Lisa L ^b   Harmatz, Jerold S ^b   Ehrenberg, Bruce L ^b   Harrel, Lisa M ^b   Corbett, Kate ^b   Counihan, Molly ^b   Tobias, Sara ^b   Shader, Richard I ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; KETOCONAZOLE; TRIAZOLAM;

AREA UNDER THE CURVE; ARTICLE; BETA RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG TRANSFORMATION; HUMAN; LIVER MICROSOME; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECALL;

ADMINISTRATION, ORAL; ADULT; ALPRAZOLAM; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; HUMANS; HYPNOTICS AND SEDATIVES; KETOCONAZOLE; MALE; REFERENCE VALUES; TIME FACTORS; TRIAZOLAM;

EID: 13144307073     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90172-2     Document Type: Article

References (35)

1. Greenblatt DJ, Wright CE. Clinical pharmacokinetics of alprazolam: therapeutic implications. Clin Pharmacokinet 1993;24:453-71.
2. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989;36:89-96.
3. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996;276:370-9.
4. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI, Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994;38:23-31.
5. Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. Inhibition of human Cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies. J Clin Pharmacol 1996;36:792-8.
6. Friedman H, Greenblatt DJ, Burstein ES, Harmatz JS, Shader RI. Population study of triazolam pharmacokinetics. Br J Clin Pharmacol 1986;22:639-42.
7. Kroboth PD, McAuley JW, Kroboth FJ, Bertz RJ, Smith RB. Triazolam pharmacokinetics after intravenous, oral and sublingual administration. J Clin Psychopharmacol 1995;15:259-62.
8. Vanderveen RP, Jirak JL, Peters GR, Cox SR, Bombardt PA. Effect of ranitidine on the disposition of orally and intravenously administered triazolam. Clinical Pharm 1991;10:539-43.
9. Smith RB, Kroboth PD, Vanderlugt JT, Phillips JP, Juhl RP. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration.Psychopharmacology (Berl) 1984;84:452-6.
10. Lin KM, Lau J, Smith R, Phillips P, Antal E, Poland R. Comparison of alprazolam plasma levels in normal Asian and Caucasian male volunteers. Psychopharmacology (Berl) 1988;96:365-9.
11. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601-7.
12. Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev 1987;39:1-47.
13. Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975;18: 377-90.
14. Pond SM, Tozer TN. First-pass elimination: basic concepts and clinical consequences. Clin Pharmacokinet 1984;9:125.
15. Greenblatt DJ. Presystemic extraction: mechanisms and consequences. J Clin Pharmacol 1993;33:650-6.
16. Greenblatt DJ, von Moltke LL, Shader RI. The importance of presystemic extraction in clinical psychopharmacology. J Clin Psychopharmacol 1996;16:417-9.
17. Greenblatt DJ, Harmatz JS, Gouthro TA, Locke J, Shader RI. Distinguishing a benzodiazepine agonist (triazolam) from a non-agonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. Clin Pharmacol Ther 1994;56:100-11.
18. Greenblatt DJ, Ehrenberg BL, Gunderman J, Scavone JM, Tai NT, Harmatz JS, et al. Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. J Pharmacol Exp Ther 1989;250:134-40.
19. Greenblatt DJ, Ehrenberg BL, Gunderman J, Locniskar A, Scavone JM, Harmatz JS, et al. Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. Clin Pharmacol Ther 1989;45:356-65.
20. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Cotreau MM, Harmatz JS, et al. Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol 1997;37:693-703.
21. Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, Shader RI. Sensitivity to triazolam in the elderly. N Engl J Med 1991;324:1691-8.
22. Shader RI, Dreyfuss D, Gerrein JR, Harmatz JS, Allison SJ, Greenblatt DJ. Sedative effects and impaired learning and recall following single oral doses of lorazepam. Clin Pharmacol Ther 1986;39:526-9.
23. Greenblatt DJ, Javaid JI, Locniskar A, Harmatz JS, Shader RI. Gas chromatographic analysis of alprazolam in plasma: replicability, stability, and specificity. J Chromatogr 1990;534:202-7.
24. Greenblatt DJ, Divoll M, Moschitto LJ, Shader RI. Electron-capture gas chromatographic analysis of the triazolobenzodiazepines alprazolam and triazolam. J Chromatogr 1981;225:202-7.
25. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268:1278-83.
26. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 1998;55:113-22.
27. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988;14:13-34.
28. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994;330:263-72.
29. Shader RI, von Moltke LL, Schmider J, Harmatz JS, Greenblatt DJ. The clinician and drug interactions - an update. J Clin Psychopharmacol 1996;16:197-201.
30. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI. Metabolism of drugs by cytochrome P450 3A isoforms: implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995;29(suppl 1):33-43.
31. Schmider J, Greenblatt DJ, von Moltke LL, Shader RI. Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans. J Clin Psychopharmacol 1996;16:267-72.
32. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-58.
33. Laurijssens BE, Greenblatt DJ. Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin Pharmacokinet 1996;30:52-76.
34. Mandema JW, Danhof M. Electroencephalogram effects measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs. Clin Pharmacokinet 1992;23:191-215.
35. Fahey JM, Pritchard GA, von Moltke LL, Pratt JS, Grassi JM, Shader RI, Greenblatt DJ. The effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. J Pharmacol Exp Ther 1998;285:271-6.